Welcome to Caroline Imbert, Research Engineer, Cell-Scale Platform
Holding a PhD in onco-immunology, Caroline Imbert took her first steps in innovative therapies in the United States, in Wisconsin, with ioGenetics. After studying at Paul Sabatier University (Toulouse III), she completed her doctoral research at the Toulouse Cancer Research Center, focusing on the study of antitumor immune responses and their regulation by sphingosine kinase-1 in cutaneous melanoma. Based in Marseille for over five years, she recently joined Marseille Immunology Biocluster as a research engineer on the Cell-Scale platform, at the core of cellular therapy development activities.
What first attracted you to immunology?
My first exposure to immunology came during an internship in a private laboratory in the United States.
I quickly worked with advanced technologies and saw how discoveries could be directly translated into new therapies. It was a real turning point for me: immunology had a tangible impact on human health.
How would you describe your professional background?
I hold a PhD in onco-immunology and have more than 10 years of experience in biomedical research.
I have developed expertise in tumor immunology, immunotherapy and preclinical studies of therapeutic antibodies, with a strong translational focus and close collaboration with both academic and industrial teams.
What excites you most about your role at MIB?
Working at the nexus of fundamental research and real-world applications. On the Cell-Scale platform,
I contribute directly to scientific innovation by working with advanced technologies and collaborating with multidisciplinary teams. This dynamic makes every day stimulating.
Partager
Actualités